机构:[1]Department of General Surgery, The Second People's Hospital of Guangdong Province, Guangzhou 510317, P.R. China.[2]Department of General Surgery, The School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, P.R. China.[3]Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P.R. China.
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that the control β‑actin western blots shown in Figs. 1B and 6 were strikingly similar to data that had already appeared in a different form in the following publication: Lei Y, Liu H, Yang Y, Wang X, Ren N, Li B, Liu S, Cheng J, Fu X and Zhang J: Interaction of LHBs with C53 promotes hepatocyte mitotic entry: A novel mechanism for HBV‑induced hepatocellular carcinoma. Oncol Rep 29: 151‑159, 2012. Owing to the fact that the contentious data in the above article had already been published prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they accepted the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 28: 311‑318, 2012; DOI: 10.3892/or.2012.1788].
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2025]版:
大类|3 区医学
小类|4 区肿瘤学
第一作者:
第一作者机构:[1]Department of General Surgery, The Second People's Hospital of Guangdong Province, Guangzhou 510317, P.R. China.
推荐引用方式(GB/T 7714):
Wang Hanning,Liu Hao,Chen Kaiyun,et al.Retracted] SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling[J].Oncology reports.2023,49(6):doi:10.3892/or.2023.8547.
APA:
Wang Hanning,Liu Hao,Chen Kaiyun,Xiao Jinfeng,He Ke...&Xiang Guoan.(2023).Retracted] SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling.Oncology reports,49,(6)
MLA:
Wang Hanning,et al."Retracted] SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling".Oncology reports 49..6(2023)